Zobrazeno 1 - 10
of 116
pro vyhledávání: '"H, Boxenbaum"'
Autor:
H, Boxenbaum
Publikováno v:
Pharmaceutical research. 1(2)
A new method employing the principle of superimposition was developed to aid in the formulation of sustained-release dosage forms. Independently absorbed components of a product, e.g., waxed pellets for an oral capsule, are administered separately an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c23c3f3d4a585990c492ff81e0af5637
https://pubmed.ncbi.nlm.nih.gov/24277217
https://pubmed.ncbi.nlm.nih.gov/24277217
Autor:
H Boxenbaum
Publikováno v:
Humanexperimental toxicology. 19(6)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::511eba7232761dad1da08b03c36609de
https://pubmed.ncbi.nlm.nih.gov/10962499
https://pubmed.ncbi.nlm.nih.gov/10962499
Autor:
H, Boxenbaum
Publikováno v:
Journal of pharmacypharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2(3)
The purpose of this note is to posit and discuss the concept of "competitive inhibition potential" (CIP), which is an in vivo index of the ability of a competitive inhibitor to elevate plasma concentrations of drug substrates, when the competitive in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ed1f0a6c50293b45cceddf86620a452a
https://pubmed.ncbi.nlm.nih.gov/10953254
https://pubmed.ncbi.nlm.nih.gov/10953254
Autor:
H, Boxenbaum
Publikováno v:
Journal of pharmacypharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 2(2)
Assuming complete hepatic substrate metabolism and system linearity, quantitative effects of in vivo competitive inhibition are investigated. Following oral administration of a substrate in the presence of a competitive inhibitor, determination of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c0c710b5740233b15c6d4742db7d8c3
https://pubmed.ncbi.nlm.nih.gov/10952769
https://pubmed.ncbi.nlm.nih.gov/10952769
Autor:
H, Boxenbaum
Publikováno v:
Journal of pharmacypharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques. 1(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e07ccdd9dee9a084e3edf9daa9e01d7b
https://pubmed.ncbi.nlm.nih.gov/10948394
https://pubmed.ncbi.nlm.nih.gov/10948394
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 27(6)
There are a variety of methods available to calculate the inhibition constant (Ki) that characterizes substrate inhibition by a competitive inhibitor. Linearized versions of the Michaelis-Menten equation (e.g., Lineweaver-Burk, Dixon, etc.) are frequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c649e36be45ae4f7df0fe3abcd89f04a
https://pubmed.ncbi.nlm.nih.gov/10348808
https://pubmed.ncbi.nlm.nih.gov/10348808
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P96
Introduction Rifaximin (RFX) is a poorly absorbed, rifamycin S derived antibiotic with broad-spectrum bactericidal activity undergoing evaluation for the treatment of traveler's diarrhea. Objective: To evaluate the effect of RFX on the pharmacokineti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce16f8d4e33acc3c689dadacbe84ef0d
https://doi.org/10.1016/j.clpt.2003.11.366
https://doi.org/10.1016/j.clpt.2003.11.366
Publikováno v:
Clinical Pharmacology & Therapeutics. 75:P66
Introduction Rifaximin (RFX) is a broad-spectrum, poorly absorbed, rifamycin S derived antibiotic being developed to treat traveler's diarrhea. Objective: To evaluate the effect of RFX on the PK of IV and PO midazolam (MDZ), a CYP 3A probe. Methods:
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aea2711af34673d3b37a5803d284f4ee
https://doi.org/10.1016/j.clpt.2003.11.246
https://doi.org/10.1016/j.clpt.2003.11.246
Autor:
J. E. Mendelson, H. Boxenbaum, D. S. Harris, N. Uemura, R. P. Nath, E. T. Everhart, R. T. Jones
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:P91-P91
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f82be347248044f1b47a17af46127d86
https://doi.org/10.1016/s0009-9236(03)90689-8
https://doi.org/10.1016/s0009-9236(03)90689-8
Autor:
H. Boxenbaum, R. Ronfeld
Publikováno v:
Pharmacokinetics ISBN: 9781461297253
As part of the pharmacokinetic ground plan, interspecies variations are considered and treated as a property and consequence of body size (allometry) and longevity. In 10 mammalian species other than man, antipyrine intrinsic clearance of unbound dru
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35b607366375a64225118c0ba30f6e58
https://doi.org/10.1007/978-1-4613-2799-8_38
https://doi.org/10.1007/978-1-4613-2799-8_38
